The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Perspective
BUSINESS AND MEDICINE

Volume 351:523-526 August 5, 2004 Number 6
NextNext

The Antibiotic Pipeline — Challenges, Costs, and Values
Richard P. Wenzel, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
 by Lerner, P. I.
-PubMed Citation
In 1941, Skinner and Keefer vividly chronicled an astonishing 82 percent mortality among 122 consecutive patients who had been treated for Staphylococcus aureus bacteremia in the preantibiotic era.1 Of the 41 patients older than 50 years of age, only 1 (2 percent) survived. Imagine the elation a few years later over the availability of penicillin, the prototype of a new therapeutic class of drugs (see page 524). In the next few decades, well-intentioned academic leaders predicted the demise of bacterial infections.

(Figure)

Figure Removed (Available Only in the Full Text)
View larger version (27K):
[in this window]
[in a new window]
 
Penicillin G.

 
Such irrational exuberance over the sustained benefits of antibiotics should have been tempered by . . . [Full Text of this Article]


Source Information

From the Department of Internal Medicine, Virginia Commonwealth University, Richmond.


Related Letters:

The Antibiotic Pipeline
Kunin C. M., Montgomery A. B.
Extract | Full Text | PDF  
N Engl J Med 2004; 351:2019-2020, Nov 4, 2004. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.